Published in Women's Health Weekly, November 26th, 2009
"Abraxane, a newer, Cremophor-free form of albumin bound paclitaxel has demonstrated an activity and an improved toxicity profile in breast and lung cancers. Five patients with gynecologic cancers (2 ovarian, 2 endometrial, and I cervical malignancy) received Abraxane after having a hypersensitivity reaction to paclitaxel. All five patients tolerated Abraxane well, experiencing no reactions or major side...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly